I. Overview of Analytical Issues for Heart
Failure Biomarkers
A. Background
In 2005, the IFCC C-SMCD recommended analytical and pre-analytical quality specifications for natriuretic peptide and their related co-metabolites assays. 1 The objectives developed were intended to guide manufacturers of commercial assays and clinical laboratories that utilize these assays. The overall goal was to establish uniform criteria so that the analytical qualities and clinical performance of assays natriuretic peptide and their related co-metabolites could be evaluated objectively. As B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) become more heavily integrated into clinical practice as diagnostic and prognostic biomarkers, understanding the differences between individual assays becomes important. Further, the influence of clinical, analytical and preanalytical factors on the growing number of BNP and NT-proBNP assays commercially available begs for a better understanding of how to interpret findings of different studies predicated on BNP or NT-proBNP concentrations monitored by different assays. The Laboratory Medicine community must also work closely with the in vitro diagnostics companies to assist in defining all of the assay characteristics, 1 a process that was poorly orchestrated during the developmental phase of cardiac troponin assays. When BNP or NT-proBNP assays are used as biomarkers for diagnosis, therapy decisions, and prognosis, or used in clinical trials or studies, they should be well characterized, as suggested by the list of recommendations that follow. We recommend that when designing studies that will use BNP or NT-proBNP assays, investigators should review the STARD (Standards for Reporting Diagnostic Accuracy) initiative 2 for both assay characterization issues as well as for clinical study design and patient enrollment issues. We also advocate that both analytic and clinical assay validation studies, including reference ("normal") interval studies, be published in detail in the peer reviewed literature. Assays that do not provide adequate information for evaluation should be used with caution. To our knowledge these recommendations are the first international recommendations addressing the analytical aspects of BNP and NT-proBNP for clinical use in heart failure. 
II. Analytical Biomarker Issues

Caution should be exercised in interpreting <50%
concentration changes as being related to medical therapy because a consistently high biological variation for both BNP and NT-proBNP exists. However, consistent trends should be followed as clinically important (Level of Evidence: B).
Scope of BNP and NT-proBNP Assays
The growing diversity of BNP and NT-proBNP assays used worldwide emphasizes the need for both analytical and clinical validation of all commercial assays prior to the clinical acceptance of these new biomarkers. 
Biological Implications for Assays of BNP and NT-proBNP
BNP and NT-proBNP concentrations are determined by various immunoassays using antibodies directed to different epitopes located on the antigen molecules. For BNP one antibody binds to the ring structure and the other antibody to either the carboxy-or amino-terminal end. Both glycosylation and degradation of BNP (amino acid residues 77 to 108) is known to occur by proteolytic cleavage of serine and proline residues at the amino-terminal end in vivo and in vitro. 1, 4, 5, 8 Both processes may effect BNP recognition by antibodies and thus be responsible for differences in stabilities of BNP measured by different commercial BNP assays. 6 Experimental observations have shown that proBNP, the precursor peptide that splits into BNP and NT-proBNP, cross reacts with commercial BNP assays. 7, 8, 9 For NT-proBNP (amino acid residues 1-76) measurement, an improved understanding of potential crossreactivity with split products of NT-proBNP and proBNP (amino acid residues 1-108) itself are needed, as preliminary evidence demonstrates cross reactivity of proBNP in an NT-proBNP assay. 8, 10 For both BNP and NT-proBNP assays blocking antibody strategies minimizing interferences from heterophilic antibodies and rheumatoid factor, for example, need to be described.
Specimen Collection for BNP and NT-proBNP Measurement
The stabilizing or destabilizing influence of anticoagulant additives, as well as the type of collection tube, have also been addressed. 11, 12 For BNP, EDTA anticoagulated whole blood or plasma appears to be the only acceptable specimen choice. Presently, only the Biosite Triage and Abbott's Point-of-Care i-STAT allow for the direct measurement of whole blood (EDTA) BNP. Samples should ideally be collected in iced tubes and processed rapidly to avoid in vitro degradation. For NT-proBNP, serum or heparin plasma is the specimen of choice on the larger instruments in clinical laboratories. EDTA plasma gives a consistent negative bias (8% to 10%) compared with matched serum samples for NT-proBNP. At least four whole blood assays (Roche Cardiac Reader, Dade Behring Stratus CS, Synx Pharma (Nanogen) StatusFirst, and Mitsubishi Pathfast) are commercially available for NT-proBNP determination. Blood collected in plastic tubes is necessary for BNP, while for NT-proBNP, either glass or plastic are acceptable. For proBNP a research assay has been developed. 7 
Clinical Impact of BNP and NT-proBNP Metabolism
In the clinical setting, BNP and NT-proBNP assay characteristics need to be better understood or better established for optimal consideration as diagnostic and prognostic biomarkers. Recent observations report that proBNP appears to show cross reactivity with at least the Biosite and Bayer BNP assays, 7, 8 conflicting with a report demonstrating that neither the Biosite or Shionogi BNP assays detect proBNP. 13 This may explain why at least one study describes difficulty for detecting BNP (amino acid residues 77-108) in plasma of patients with severe heart failure and increased BNP concentrations by Biosite assay, when a non-immunologic measurement approach (ie, liquid chromatography (LC)-electrospray ionization Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry) was used. 14 Release of intact proBNP in its glycosylated and deglycosylated forms in blood may, therefore, have substantial implications regarding clinical utilization of BNP and NT-proBNP assays. 7,8,9,10,13
Other Effects and Considerations for BNP and NT-proBNP Values
The influence of age, gender, ethnicity, and non-HF pathologies have been shown to substantially influence what may otherwise be considered a physiological concentration. 15, 16 Renal impairment has been shown to increase NT-proBNP concentrations and increase BNP to a lesser extent. [17] [18] [19] Obesity has also been shown to have an impact on BNP and NT-proBNP concentrations, with an inverse relationship between body mass index (BMI) and BNP and NT-proBNP concentrations in patients with and without CHF. 20 -22 It appears some of this variability is related to lean body mass, perhaps as a manifestation of testosterone metabolism. It appears that androgens reduce BNP and NT-proBNP levels. 23 HF patients who receive the drug nesiritide (Natracor, human recombinant BNP) for therapy and management may have confounding BNP results, since nesiritide is molecularly identical to endogenously released BNP. Thus, if BNP concentrations were to be monitored for regulation of nesiritide infusion within a time window before an appropriate decrease of BNP could occur (theoretical half-life Ϸ22 minutes), the potential for false increased concentrations could arise. Conversely, Nesiritide does not directly confound NT-proBNP measurements. Changes in NT-proBNP in response to nesiritide have not been marked in most studies. 24, 25 Finally, a lack of definitive understanding of the biological variability of BNP and NT-proBNP may cause clinicians to misinterpret changing (increasing or decreasing) BNP and NT-proBNP concentrations in the context of establishing the success or failure of therapy. Both BNP and NT-proBNP have been shown to exhibit a high intra-individual biological variability. 26 -29 Thus when considering what is significantly different between serial BNP or NT-proBNP concentrations for clinical use, a change of approximately 85% for increases and 46% for decreases could at minimum be necessary. This implies that changes in BNP or NT-proBNP concentrations must be used cautiously and reemphasizes their role as confirmation biomarkers and not as stand alone tests that clinicians should solely rely on to manage HF patients.
The literature is scattered with home-brewed BNP and NT-proBNP assays that may add to the confusion of clinicians when interpreting and comparing data from different clinical studies. To avoid misinterpretation of results, one must consider the assay used, the available clinical evidence based on that individual assay, together with the clinical aim of an individual biomarker based study. Due to the lack of a single molecular natriuretic peptide or metabolic entity in the serum, plasma or whole blood matrix tested and the crossreactivity of the antibodies used toward these various NP forms, results for both BNP and NT-proBNP should be reported in ng/L, rather than pmol/L. No peer-reviewed literature has demonstrated that two NP assays are analytically equivalent. Until large studies are available, caution is suggested before the conclusions based on one BNP or one NT-proBNP assay-based study are translated to another assay-based context. Indeed, studies directed toward different clinical populations will often have very different cutoff concentrations. A synthesis of the rule in and rule out cutoffs for each clinical scenario is needed for the heart failure field to advance. 30 
